Eagle Pharmaceuticals (EGRX) Reports In-Line Q1 EPS

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.42, in-line with the analyst estimate of $1.42. Revenue for the quarter came in at $76.8 million versus the consensus estimate of $70.37 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• FGI Industries Ltd (FGI) Tops Q2 EPS by 59c